J.M. Adam, D.J. Bennett, A. Bom, J.K. Clark i inni. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. „J Med Chem”. 45 (9), s. 1806–1816, 2002. DOI: 10.1021/jm011107f. PMID: 11960492.
G.J. Tarver, S.J. Grove, K. Buchanan, A. Bom i inni. 2-O-substituted cyclodextrins as reversal agents for the neuromuscular blocker rocuronium bromide. „Bioorg Med Chem”. 10 (6), s. 1819–1827, 2002. DOI: 10.1016/S0968-0896(02)00026-3. PMID: 11937340.
H.D. de Boer, J. van Egmond, F. van de Pol, A. Bom i inni. Sugammadex, a new reversal agent for neuromuscular block induced by rocuronium in the anaesthetized Rhesus monkey. „Br J Anaesth”. 96 (4), s. 473–479, 2006. DOI: 10.1093/bja/ael013. PMID: 16464982.
M.E. Davis, M.E. Brewster. Cyclodextrin-based pharmaceutics: past, present and future. „Nat Rev Drug Discov”. 3 (12), s. 1023–1035, 2004. DOI: 10.1038/nrd1576. PMID: 15573101.
T.D. Egan, S.E. Kern, K.B. Johnson, N.L. Pace. The pharmacokinetics and pharmacodynamics of propofol in a modified cyclodextrin formulation (Captisol) versus propofol in a lipid formulation (Diprivan): an electroencephalographic and hemodynamic study in a porcine model. „Anesth Analg”. 97 (1), s. 72–79, table of contents, 2003. DOI: 10.1213/01.ANE.0000066019.42467.7A. PMID: 12818946.
J.P. Estebe, C. Ecoffey, G. Dollo, P. Le Corre i inni. Bupivacaine pharmacokinetics and motor blockade following epidural administration of the bupivacaine-sulphobutylether 7-beta-cyclodextrin complex in sheep. „Eur J Anaesthesiol”. 19 (4), s. 308–310, 2002. DOI: 10.1017/S0265021502260494. PMID: 12074425.
M. Welliver, J. McDonough, N. Kalynych, R. Redfern. Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent. „Drug Des Devel Ther”. 2, s. 49–59, 2009. DOI: 10.2147/DDDT.S2757. PMID: 19920893. PMCID: PMC2761174.
A.M. Fields, N. Vadivelu. Sugammadex: a novel neuromuscular blocker binding agent. „Curr Opin Anaesthesiol”. 20 (4), s. 307–310, 2007. DOI: 10.1097/ACO.0b013e32814b1612. PMID: 17620836.
R. Challa, A. Ahuja, J. Ali, R.K. Khar. Cyclodextrins in drug delivery: an updated review. „AAPS PharmSciTech”. 6 (2), s. E329-57, 2005. DOI: 10.1208/pt060243. PMID: 16353992. PMCID: PMC750546.
B.F. Vanacker, K.M. Vermeyen, M.M. Struys, H. Rietbergen i inni. Reversal of rocuronium-induced neuromuscular block with the novel drug sugammadex is equally effective under maintenance anesthesia with propofol or sevoflurane. „Anesth Analg”. 104 (3), s. 563–568, 2007-03-01. DOI: 10.1213/01.ane.0000231829.29177.8e. PMID: 17312209.
O. Epemolu, A. Bom, F. Hope, R. Mason. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. „Anesthesiology”. 99 (3), s. 632–637, 2003. DOI: 10.1097/00000542-200309000-00018. PMID: 12960547.
F. Gijsenbergh, S. Ramael, N. Houwing, T. van Iersel. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. „Anesthesiology”. 103 (4), s. 695–703, 2005. DOI: 10.1097/00000542-200510000-00007. PMID: 16192761.
H.D. de Boer, J.J. Driessen, M.A. Marcus, H. Kerkkamp i inni. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. „Anesthesiology”. 107 (2), s. 239–244, 2007. DOI: 10.1097/01.anes.0000270722.95764.37. PMID: 17667567.
H.J. Sparr, K.M. Vermeyen, A.M. Beaufort, H. Rietbergen i inni. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. „Anesthesiology”. 106 (5), s. 935–943, 2007. DOI: 10.1097/01.anes.0000265152.78943.74. PMID: 17457124.
O. Epemolu, I. Mayer, F. Hope, P. Scullion i inni. Liquid chromatography/mass spectrometric bioanalysis of a modified gamma-cyclodextrin (Org 25969) and Rocuronium bromide (Org 9426) in guinea pig plasma and urine: its application to determine the plasma pharmacokinetics of Org 25969. „Rapid Commun Mass Spectrom”. 16 (20), s. 1946–1952, 2002. DOI: 10.1002/rcm.812. PMID: 12362386.
F.K. Pühringer, C. Rex, A.W. Sielenkämper, C. Claudius i inni. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. „Anesthesiology”. 109 (2), s. 188–197, 2008. DOI: 10.1097/ALN.0b013e31817f5bc7. PMID: 18648227.
P. Duvaldestin, K. Kuizenga, V. Saldien, C. Claudius i inni. A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia. „Anesth Analg”. 110 (1), s. 74–82, 2010. DOI: 10.1213/ANE.0b013e3181c3be3c. PMID: 19933538.
O. Sacan, P.F. White, B. Tufanogullari, K. Klein. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine. „Anesth Analg”. 104 (3), s. 569–574, 2007. DOI: 10.1213/01.ane.0000248224.42707.48. PMID: 17312210.
E.A. Flockton, P. Mastronardi, J.M. Hunter, C. Gomar i inni. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. „Br J Anaesth”. 100 (5), s. 622–630, 2008. DOI: 10.1093/bja/aen037. PMID: 18385265.
B. Plaud, O. Meretoja, R. Hofmockel, J. Raft i inni. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. „Anesthesiology”. 110 (2), s. 284–294, 2009. DOI: 10.1097/ALN.0b013e318194caaa. PMID: 19194156.
L.M. Staals, M.M. Snoeck, J.J. Driessen, H.W. van Hamersvelt i inni. Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study. „Br J Anaesth”. 104 (1), s. 31–39, 2010. DOI: 10.1093/bja/aep340. PMID: 20007792.
V. Dahl, P.E. Pendeville, M.W. Hollmann, T. Heier i inni. Safety and efficacy of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in cardiac patients undergoing noncardiac surgery. „Eur J Anaesthesiol”. 26 (10), s. 874–884, 2009. DOI: 10.1097/EJA.0b013e32832c605b. PMID: 19455040.
A. Bom, F. Hope, S. Rutherford, K. Thomson. Preclinical pharmacology of sugammadex. „J Crit Care”. 24 (1), s. 29–35, 2009. DOI: 10.1016/j.jcrc.2008.10.010. PMID: 19272536.
A. Srivastava, J.M. Hunter. Reversal of neuromuscular block. „Br J Anaesth”. 103 (1), s. 115–129, 2009. DOI: 10.1093/bja/aep093. PMID: 19468024.
D.J. Eleveld, K. Kuizenga, J.H. Proost, J.M. Wierda. A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex. „Anesth Analg”. 104 (3), s. 582–584, 2007. DOI: 10.1213/01.ane.0000250617.79166.7f. PMID: 17312212.
G. Cammu, P.J. De Kam, I. Demeyer, M. Decoopman i inni. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers. „Br J Anaesth”. 100 (3), s. 373–379, 2008. DOI: 10.1093/bja/aem402. PMID: 18238834.
dx.doi.org
Anton BomA.B.Dr.Anton BomA.B. i inni, A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host, „Angewandte Chemie International Edition”, 41 (2), 2002, s. 266–270, DOI: 10.1002/1521-3773(20020118)41:2<265::AID-ANIE265>3.0.CO;2-Q, PMID: 12491405.
Max T.M.T.BakerMax T.M.T., MohamedM.NaguibMohamedM., Propofol: the challenges of formulation, „Anesthesiology”, 103 (4), 2005, s. 860–876, DOI: 10.1097/00000542-200510000-00026, PMID: 16192780.
Anton BomA.B.Dr.Anton BomA.B. i inni, A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host, „Angewandte Chemie International Edition”, 41 (2), 2002, s. 266–270, DOI: 10.1002/1521-3773(20020118)41:2<265::AID-ANIE265>3.0.CO;2-Q, PMID: 12491405.
J.M. Adam, D.J. Bennett, A. Bom, J.K. Clark i inni. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. „J Med Chem”. 45 (9), s. 1806–1816, 2002. DOI: 10.1021/jm011107f. PMID: 11960492.
G.J. Tarver, S.J. Grove, K. Buchanan, A. Bom i inni. 2-O-substituted cyclodextrins as reversal agents for the neuromuscular blocker rocuronium bromide. „Bioorg Med Chem”. 10 (6), s. 1819–1827, 2002. DOI: 10.1016/S0968-0896(02)00026-3. PMID: 11937340.
H.D. de Boer, J. van Egmond, F. van de Pol, A. Bom i inni. Sugammadex, a new reversal agent for neuromuscular block induced by rocuronium in the anaesthetized Rhesus monkey. „Br J Anaesth”. 96 (4), s. 473–479, 2006. DOI: 10.1093/bja/ael013. PMID: 16464982.
M. Welliver. New drug sugammadex: a selective relaxant binding agent. „AANA J”. 74 (5), s. 357–363, 2006. PMID: 17048555.
D.O. Thompson. Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals. „Crit Rev Ther Drug Carrier Syst”. 14 (1), s. 1–104, 1997. PMID: 9043816.
M.E. Davis, M.E. Brewster. Cyclodextrin-based pharmaceutics: past, present and future. „Nat Rev Drug Discov”. 3 (12), s. 1023–1035, 2004. DOI: 10.1038/nrd1576. PMID: 15573101.
T.D. Egan, S.E. Kern, K.B. Johnson, N.L. Pace. The pharmacokinetics and pharmacodynamics of propofol in a modified cyclodextrin formulation (Captisol) versus propofol in a lipid formulation (Diprivan): an electroencephalographic and hemodynamic study in a porcine model. „Anesth Analg”. 97 (1), s. 72–79, table of contents, 2003. DOI: 10.1213/01.ANE.0000066019.42467.7A. PMID: 12818946.
Max T.M.T.BakerMax T.M.T., MohamedM.NaguibMohamedM., Propofol: the challenges of formulation, „Anesthesiology”, 103 (4), 2005, s. 860–876, DOI: 10.1097/00000542-200510000-00026, PMID: 16192780.
H. Gudmundsdottir, J.F. Sigurjonsdottir, M. Masson, O. Fjalldal i inni. Intranasal administration of midazolam in a cyclodextrin based formulation: bioavailability and clinical evaluation in humans. „Pharmazie”. 56 (12), s. 963–966, 2001. PMID: 11802661.
J.P. Estebe, C. Ecoffey, G. Dollo, P. Le Corre i inni. Bupivacaine pharmacokinetics and motor blockade following epidural administration of the bupivacaine-sulphobutylether 7-beta-cyclodextrin complex in sheep. „Eur J Anaesthesiol”. 19 (4), s. 308–310, 2002. DOI: 10.1017/S0265021502260494. PMID: 12074425.
T.F. Meert, J. Mesens, P. Verheyen, H. Noorduin. Hydroxypropyl-beta-cyclodextrin can modulate the activity of spinally administered sufentanil. „Eur J Anaesthesiol”. 9 (5), s. 399–409, 1992. PMID: 1396627.
M. Welliver, J. McDonough, N. Kalynych, R. Redfern. Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent. „Drug Des Devel Ther”. 2, s. 49–59, 2009. DOI: 10.2147/DDDT.S2757. PMID: 19920893. PMCID: PMC2761174.
A.M. Fields, N. Vadivelu. Sugammadex: a novel neuromuscular blocker binding agent. „Curr Opin Anaesthesiol”. 20 (4), s. 307–310, 2007. DOI: 10.1097/ACO.0b013e32814b1612. PMID: 17620836.
R. Challa, A. Ahuja, J. Ali, R.K. Khar. Cyclodextrins in drug delivery: an updated review. „AAPS PharmSciTech”. 6 (2), s. E329-57, 2005. DOI: 10.1208/pt060243. PMID: 16353992. PMCID: PMC750546.
B.F. Vanacker, K.M. Vermeyen, M.M. Struys, H. Rietbergen i inni. Reversal of rocuronium-induced neuromuscular block with the novel drug sugammadex is equally effective under maintenance anesthesia with propofol or sevoflurane. „Anesth Analg”. 104 (3), s. 563–568, 2007-03-01. DOI: 10.1213/01.ane.0000231829.29177.8e. PMID: 17312209.
O. Epemolu, A. Bom, F. Hope, R. Mason. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. „Anesthesiology”. 99 (3), s. 632–637, 2003. DOI: 10.1097/00000542-200309000-00018. PMID: 12960547.
F. Gijsenbergh, S. Ramael, N. Houwing, T. van Iersel. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. „Anesthesiology”. 103 (4), s. 695–703, 2005. DOI: 10.1097/00000542-200510000-00007. PMID: 16192761.
H.D. de Boer, J.J. Driessen, M.A. Marcus, H. Kerkkamp i inni. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. „Anesthesiology”. 107 (2), s. 239–244, 2007. DOI: 10.1097/01.anes.0000270722.95764.37. PMID: 17667567.
I.F. Sorgenfrei, K. Norrild, P.B. Larsen, J. Stensballe i inni. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. „Anesthesiology”. 104 (4), s. 667–674, 2006. PMID: 16571960.
H.J. Sparr, K.M. Vermeyen, A.M. Beaufort, H. Rietbergen i inni. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. „Anesthesiology”. 106 (5), s. 935–943, 2007. DOI: 10.1097/01.anes.0000265152.78943.74. PMID: 17457124.
O. Epemolu, I. Mayer, F. Hope, P. Scullion i inni. Liquid chromatography/mass spectrometric bioanalysis of a modified gamma-cyclodextrin (Org 25969) and Rocuronium bromide (Org 9426) in guinea pig plasma and urine: its application to determine the plasma pharmacokinetics of Org 25969. „Rapid Commun Mass Spectrom”. 16 (20), s. 1946–1952, 2002. DOI: 10.1002/rcm.812. PMID: 12362386.
F.K. Pühringer, C. Rex, A.W. Sielenkämper, C. Claudius i inni. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. „Anesthesiology”. 109 (2), s. 188–197, 2008. DOI: 10.1097/ALN.0b013e31817f5bc7. PMID: 18648227.
K. Suy, K. Morias, G. Cammu, P. Hans i inni. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. „Anesthesiology”. 106 (2), s. 283–288, 2007. PMID: 17264722.
P. Duvaldestin, K. Kuizenga, V. Saldien, C. Claudius i inni. A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia. „Anesth Analg”. 110 (1), s. 74–82, 2010. DOI: 10.1213/ANE.0b013e3181c3be3c. PMID: 19933538.
O. Sacan, P.F. White, B. Tufanogullari, K. Klein. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine. „Anesth Analg”. 104 (3), s. 569–574, 2007. DOI: 10.1213/01.ane.0000248224.42707.48. PMID: 17312210.
E.A. Flockton, P. Mastronardi, J.M. Hunter, C. Gomar i inni. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. „Br J Anaesth”. 100 (5), s. 622–630, 2008. DOI: 10.1093/bja/aen037. PMID: 18385265.
B. Plaud, O. Meretoja, R. Hofmockel, J. Raft i inni. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. „Anesthesiology”. 110 (2), s. 284–294, 2009. DOI: 10.1097/ALN.0b013e318194caaa. PMID: 19194156.
L.M. Staals, M.M. Snoeck, J.J. Driessen, H.W. van Hamersvelt i inni. Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study. „Br J Anaesth”. 104 (1), s. 31–39, 2010. DOI: 10.1093/bja/aep340. PMID: 20007792.
V. Dahl, P.E. Pendeville, M.W. Hollmann, T. Heier i inni. Safety and efficacy of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in cardiac patients undergoing noncardiac surgery. „Eur J Anaesthesiol”. 26 (10), s. 874–884, 2009. DOI: 10.1097/EJA.0b013e32832c605b. PMID: 19455040.
A. Bom, F. Hope, S. Rutherford, K. Thomson. Preclinical pharmacology of sugammadex. „J Crit Care”. 24 (1), s. 29–35, 2009. DOI: 10.1016/j.jcrc.2008.10.010. PMID: 19272536.
A. Srivastava, J.M. Hunter. Reversal of neuromuscular block. „Br J Anaesth”. 103 (1), s. 115–129, 2009. DOI: 10.1093/bja/aep093. PMID: 19468024.
D.J. Eleveld, K. Kuizenga, J.H. Proost, J.M. Wierda. A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex. „Anesth Analg”. 104 (3), s. 582–584, 2007. DOI: 10.1213/01.ane.0000250617.79166.7f. PMID: 17312212.
G. Cammu, P.J. De Kam, I. Demeyer, M. Decoopman i inni. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers. „Br J Anaesth”. 100 (3), s. 373–379, 2008. DOI: 10.1093/bja/aem402. PMID: 18238834.